Lanreotide clinical trials: 49 trials
Page 1 of 1
Read 49 Lanreotide clinical trials with posted results or linked papers with results in PepBank.
- Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
NCT00353496 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
NCT01137682 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517 · Phase 3 · Completed
Posted results
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708 · Phase 3 · Completed
Posted results
- Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363 · Phase 4 · Completed
Posted results
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
NCT00774930 · Phase 3 · Completed
Posted results
- Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00690898 · Phase 3 · Completed
Posted results
- Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
NCT00842348 · Phase 3 · Completed
Posted results
- Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
NCT02683941 · Phase 3 · Terminated
Posted results
- Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499 · Phase 3 · Completed
Posted results
- A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
NCT02288377 · Phase 2/3 · Terminated
Posted results
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
NCT03289741 · Phase 4 · Completed
Posted results
- Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NCT02075606 · Phase 4 · Completed
Posted results
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
NCT04852679 · Phase 3 · Completed
Posted results
- Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
NCT00891371 · Phase 2/3 · Completed
Posted results
- Somatuline Autogel Preference and Health Economy Study
NCT00681187 · Phase 4 · Completed
Posted results
- A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT01861717 · Phase 4 · Terminated
Posted results
- Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
NCT01313273 · Phase 3 · Terminated
Posted results
- Study of Lanreotide to Treat Polycystic Kidney Disease
NCT01616927 · Phase 3 · Status unknown
Linked paper with results
- Lanreotide In Polycystic Kidney Disease Study
NCT02127437 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
NCT00729313 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572 · Phase 2/3 · Completed
Linked paper with results
- Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
NCT00216372 · Phase 3 · Completed
Linked paper with results
- Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 · Phase 3 · Completed
Linked paper with results
- Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993 · Phase 3 · Completed
Linked paper with results
- Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
NCT01315795 · Phase 2/3 · Completed
Linked paper with results
- Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00149188 · Phase 4 · Completed
Linked paper with results
- Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00627796 · Phase 4 · Completed
Linked paper with results
- GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
NCT00495846 · Phase 2/3 · Completed
Linked paper with results
- A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
NCT03174353 · Phase 2 · Completed
Posted results
- Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
NCT02651987 · Phase 2 · Completed
Posted results
- Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
NCT02231762 · Phase 2 · Completed
Posted results
- Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
NCT02275338 · Phase 2 · Completed
Posted results
- A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
NCT02795858 · Phase 2 · Completed
Posted results
- Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
NCT02365584 · Phase 2 · Terminated
Posted results
- Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
NCT02698410 · Phase 2 · Completed
Posted results
- Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
NCT02396953 · Phase 1/2 · Completed
Posted results
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
NCT03043664 · Phase 1/2 · Completed
Posted results
- Lanreotide in the Treatment of Small Bowel Motility Disorders
NCT03012594 · Phase 2 · Completed
Posted results
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
NCT02859064 · Phase 2 · Terminated
Posted results
- Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
NCT00993356 · Phase 2 · Status unknown
Linked paper with results
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
NCT04427787 · Phase 2 · Status unknown
Linked paper with results
- Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
NCT02351128 · Phase 2 · Completed
Linked paper with results
- Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
NCT00326469 · Phase 2 · Completed
Linked paper with results
- Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
NCT02054637 · Phase 2 · Status unknown
Linked paper with results
- The MetNET-2 Trial
NCT02823691 · Early phase 1 · Status unknown
Linked paper with results
- Acromegaly Combination Treatment Study
NCT01538966 · Not applicable · Terminated
Posted results
- Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
NCT04696042 · Phase not stated · Completed
Linked paper with results
- Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
NCT01354405 · Phase not stated · Completed
Linked paper with results